Author Archives: admin001

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

Final randomized Phase 2 Bria-IMT™ survival and quality of life data to be presented Biomarker ...

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+(TM) in Preclinical Cancer Models

Bria-OTS+ platform provides early, potent and durable activation of innate and adaptive immunity in in-vitro ...

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

Phase 3 clinical data in heavily pretreated metastatic breast cancer patients with prior failed ADC, ...

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

PHILADELPHIA and VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell to Present Positive Clinical Data for Bria-IMT(TM) and Preclinical Data for Next Generation Bria-OTS+(TM) Personalized Immunotherapy at the 2026 AACR Conference

PHILADELPHIA and VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

PHILADELPHIA and VANCOUVER, British Columbia, March 10, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Independent DSMB has identified no safety concerns, and recommends continuation of BriaCell’s pivotal Phase 3 ...

BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

Images below confirm clinical responses seen in patients with metastatic orbital (eye), temporal (brain), liver, ...